Innovus Pharma Initiates Pre-Clinical and Clinical Program Evaluating Vesele® with Sildenafil (Viagra®)
Innovus Pharma to Request Regulatory Guidance for Filing for Its FlutiCare Product in Europe for the Treatment of Allergic Rhinitis
Westport to Issue Q2 2025 Financial Results on August 11, 2025 and Provides an Update on the Divestment of the Light-Duty Segment
Blue Lagoon Resources Added to CSE25 Index - Recognized Among 25 Largest Companies on the Canadian Securities Exchange
